Saturday 17 October 2026
Export CLLS’s income statement to Excel — free account
Cellectis S.A.
CLLS Healthcare Biotechnology
Cellectis S.A.’s revenue for fiscal 2025 (year ended December 2025) was $79.6 million, up 61.7% from fiscal 2024. In the quarter to June 2026, revenue fell 62.1%, EPS grew 8.33%, free cash flow fell 37.0% and total debt was flat, each against the same quarter a year earlier.
1.04
0.07
−6.31%
Follow CLLS
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
4.73 | 4.24 | 6.10 | 3.46 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(21.14) | (20.68) | (46.85) | (182.00) | |
P/B ratio |
7.35 | 5.32 | 6.39 | 2.85 | |
Price to Tangible BV |
7.56 | 5.34 | 6.44 | 2.87 | |
EV/Sales |
3.27 | 2.79 | 4.54 | 2.12 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(5.02) | (5.56) | (9.17) | (6.03) | |
EV/FCF |
(4.52) | (4.95) | (8.18) | (5.17) | |
Quick Ratio |
1.33 | 1.48 | 1.58 | 1.46 | |
Current Ratio |
1.37 | 1.52 | 1.62 | 1.49 | |
Net Debt/EBITDA |
4.88 | 5.30 | 10.14 | (8.47) | |
Debt/Assets |
27.56% | 26.42% | 26.01% | 23.80% | |
Debt/Equity |
1.79 | 1.28 | 1.11 | 0.81 | |
Asset Turnover |
0.21 | 0.23 | 0.22 | 0.22 | |
Operating CF/Net income |
0.65 | 0.87 | 0.39 | (2.67) | |
Capex/Depreciation |
(0.06) | (0.06) | (0.10) | (0.47) | |
Interest Coverage |
(7.81) | (5.66) | (1.70) | 0.74 | |
Research and Development Expense of Revenue |
361.76% | 360.20% | 200.20% | 64.76% | |
Selling, General and Administrative Expense of Revenue |
83.13% | 74.06% | 39.34% | 14.01% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
33.15% | 22.03% | 18.43% | 4.31% | |
Graham Net Nets |
(0.14) | (0.08) | (0.03) | (0.07) | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(21.80%) | (21.26%) | (13.93%) | (20.49%) | |
Free Cash Flow Yield |
(15.30%) | (13.27%) | (9.10%) | (11.86%) | |
Revenue per Share |
0.07 | 0.08 | 0.12 | 0.37 | |
Operating CF per Share |
(0.14) | (0.15) | (0.10) | (0.02) | |
Capex per Share |
0.00 | 0.00 | 0.00 | (0.02) | |
Free Cash Flow per Share |
(0.14) | (0.16) | (0.11) | (0.04) | |
Cash per Share |
1.66 | 1.85 | 2.08 | 1.92 | |
Shareholders Equity per Share |
0.41 | 0.60 | 0.76 | 1.00 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.41 | 0.60 | 0.76 | 1.00 | |
Free Cash Flow |
(14.54) | (15.67) | (10.85) | (3.91) | |
Working Capital |
49.46 | 70.05 | 90.49 | 72.62 | |
Capital Expenditures |
(0.25) | (0.26) | (0.49) | (2.34) | |
Net Current Asset Value |
(41.88) | (24.72) | (12.57) | (21.37) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.04 | 0.04 | 0.04 | 0.06 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
18.88 | 17.87 | 21.72 | 25.65 | |
Average Payables |
17.86 | 17.15 | 17.97 | 17.30 | |
Average Assets |
310.67 | 326.64 | 354.13 | 369.46 | |
Average Common Equity |
69.09 | 88.06 | 103.47 | 114.95 |
Columns are period end dates